Mechanism of low-molecular-weight heparin reversal by platelet factor 4

被引:6
作者
Fiore, Martine M. [1 ]
Mackie, Ian M. [1 ]
机构
[1] UCL, Dept Hematol, Haemostasis Res Unit, London WC1E 6HX, England
关键词
Platelet Factor 4; Antithrombin; Heparin; Anticoagulation; PLATELET FACTOR-IV; ANTI-FACTOR XA; THROMBIN GENERATION; VENOUS THROMBOEMBOLISM; DERMATAN SULFATE; IIA ACTIVITIES; ANTITHROMBIN; BINDING; ENOXAPARIN; INHIBITION;
D O I
10.1016/j.thromres.2008.12.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Low-molecular-weight heparins (LMWH) exert their anticoagulant effect by accelerating anti-thrombin (AT) inactivation of factor Xa (fXa) and thrombin. To address the hypothesis of a calcium-dependent template mechanism in LMWH activity, we compared the ability of the heparin neutralising agent Platelet Factor 4 (PF4) to inhibit various therapeutic LMWH in a kinetic assay. Neutralization coefficients by PF4 and apparent affinities of PF4 for various LMWH increased in a molecular weight-dependent manner. Protamine sulphate neutralized heparin via a non-specific mechanism. EDTA abolished the calcium-dependent acceleration of the fXa-AT reaction, indicating that the bridging mechanism contributed significantly to LMWH activity. Within a low range of LMWH concentration (<0.2 U/ml), excess AT over PF4 (4:1) had no effect on PF4 activity, indicating that PF4 and AT binding to heparin were independent of each other. Instead, increasing enzyme concentration reversed the negative effect of heparin-bound AT on PF4-dependent neutralization. Inhibition of thrombin by heparin was also neutralized by PF4, albeit to a higher extent than the fXa-AT reaction. Altogether, these results suggested that an interaction of PF4 with protease mediated the association of PF4 to the heparin chain. We propose that PF4 participates in the anti-fXa dependence of LMWH due to its major effect on the anti-thrombin activity of LMWH and that inhibition of fXa via the template mechanism plays an essential role in LMWH activity and pharmacokinetics, because PF4 specifically targets this mechanism. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 29 条
[1]   Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery [J].
Bara, L ;
Planes, A ;
Samama, MM .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (02) :230-240
[2]  
Brieger D, 1997, THROMB HAEMOSTASIS, V77, P317
[3]  
BRIEGER D, 1994, THROMB HAEMOSTASIS, V72, P275
[4]   Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex [J].
Brufatto, N ;
Ward, A ;
Nesheim, ME .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (06) :1258-1263
[5]  
COLLIGNON F, 1995, THROMB HAEMOSTASIS, V73, P6306
[6]  
DANIELSSON A, 1986, J BIOL CHEM, V261, P5467
[7]   REVERSAL OF HEPARIN ANTICOAGULATION BY RECOMBINANT PLATELET FACTOR-4 IN HUMANS [J].
DEHMER, GJ ;
FISHER, M ;
TATE, DA ;
TEO, S ;
BONNEM, EM .
CIRCULATION, 1995, 91 (08) :2188-2194
[8]   BINDING OF PLATELET FACTOR-4 TO HEPARIN OLIGOSACCHARIDES [J].
DENTON, J ;
LANE, DA ;
THUNBERG, L ;
SLATER, AM ;
LINDAHL, U .
BIOCHEMICAL JOURNAL, 1983, 209 (02) :455-460
[9]   Comparative study of the pharmacokinetic profiles of two LMWHs - bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) - administered subcutaneously to healthy male volunteers [J].
Depasse, F ;
de Suso, MJG ;
Lagoutte, I ;
Fontcuberta, J ;
Borrell, M ;
Samama, MM .
THROMBOSIS RESEARCH, 2003, 109 (2-3) :109-117
[10]   Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. [J].
Eriksson, BI ;
Bauer, KA ;
Lassen, MR ;
Turpie, AGG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (18) :1298-1304